重组人类促红细胞生成素结合铁剂在早产儿贫血中的防治疗效

Therapeutic Efficacy of Recombinant Human Erythropoietin Combined with Oron in the Treatment of Anemia in Premature Children

目的:分析比较重组人类促红细胞生成素(erythropoietin,r Hu-EPO)结合铁剂在早产儿贫血中的防治疗效。方法:随机选择2014年1月-2015年1月本院儿科收治的68例早产儿,依据临床中不同的治疗方法将早产儿分为研究组与对照组,每组各34例。对照组应用常规贫血防治方法治疗,研究组应用重组人类促红细胞生成素结合铁剂治疗,对比两组的临床防治疗效。结果:研究组血小板(PLT)、白细胞(WBC)指标变化与对照组比较,差异均无统计学意义(P>0.05);研究组红细胞(RBC)、红细胞压积(HCT)、血红蛋白(Hb)与对照组比对比,差异均有统计学意义(P<0.05);研究组不良反应发生率为17.6%,对照组为50.0%,两组比较差异有统计学意义(P<0.05)。结论:在临床防治早产儿贫血中,应用重组人类促红细胞生成素结合铁剂治疗,可以降低早产儿贫血发生率,对改善早产儿贫血指标,降低不良反应发生情况,治疗安全性高,防治早产儿贫血发挥积极作用。

Objective：To analyze the therapeutic efficacy of Recombinant Human Erythropoietin combined with Oron in the treatment of anemia in premature children.Method：According to different treatment methods 68 cases of premature infants were randomly selected from January 2014 to January 2015,and were divided into study group and control group,34 cases in each group.The control group was given routine prevention of anemia treatment,the study group was given recombinant human erythropoietin combined with iron therapy,the effects of two groups were compared.Result：PLT,WBC of the study group had no significant differences compared with the control group（P0.05）.RBC,HCT and Hb of the study group compared with the control group,there were statistical difference（P0.05）.The incidence rate of adverse reaction of the study group was 17.6%,the control group was 50.0%,there was statistical difference（P0.05）.Conclusion：In clinical prevention and treatment of anemia of prematurity and application of recombinant human erythropoietin combined iron therapy can reduce the incidence of anemia of prematurity,improve the anemia of prematurity and the incidence of adverse reactions,has high safety,prevention and treatment of anemia of prematurity hair play a positive role.